Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017

Gadolinium-based Contrast Agents for Magnetic Resonance Imaging (MRI): Drug Safety Communication - No Harmful Effects Identified With Brain Retention

FDA says gadolinium retention in the brain is not a safety issue

May 25, 2017 — A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for magnetic resonance imaging (MRI) has not identified adverse health affects from gadolinium retained in the brain. The FDA released a drug safety communication regarding all gadolinium-based contrast agents (GBCAs) earlier this week. 

The FDA said GBCAs may be associated with some gadolinium retention in the brain and other body tissues. However, the FDA said there is no evidence to date that gadolinium retention in the brain from any of the GBCAs is harmful. The agency said this includes GBCAs associated with higher retention of gadolinium. These findings prompted the FDA say restricting GBCA use is not warranted at this time. FDA said it will continue to assess the safety of GBCAs and plan to have a public meeting to discuss this issue in the future.

The agency said it evaluated scientific publications and adverse event reports submitted to FDA. Some human and animal studies looked at GBCA use over periods longer than a year. These publications and reports show that gadolinium is retained in organs such as the brain, bones and skin. The publications show that linear GBCAs retain more gadolinium in the brain than macrocyclic GBCAs. However, the review did not identify adverse health effects related to this brain retention.

The FDA continues to assess the safety of GBCAs. FDA’s National Center for Toxicological Research is conducting a study on brain retention of GBCAs in rats. Other research is also being conducted about how gadolinium is retained in the body. FDA will update the public when new information becomes available, and a public meeting to discuss results will be held in the future.

The intravenous gadolinium contrast media specifically mentioned in the safety communication includes:
• Ablavar (gadofosveset trisodium) 
• Dotarem (gadoterate meglumine) 
• Eovist (gadoxetate disodium) 
• Gadavist (gadobutrol) 
• Magnevist (gadopentetate dimeglumine) 
• MultiHance (gadobenate dimeglumine) 
• Omniscan (gadodiamide) 
• OptiMARK (gadoversetamide) 
• ProHance (gadoteridol)

The FDA recommendations for healthcare professionals and patients remains unchanged from July 2015, when FDA first informed the public that it was investigating this potential risk with GBCAs. 

The agency said the agents should be used as is appropriate when considering the use of any medical imaging agent. It also stated healthcare professionals should limit GBCA use to circumstances in which additional information provided by the contrast agent is necessary and to assess the necessity of repetitive MRIs with GBCAs. 

The FDA said retention of gadolinium affects only GBCAs and does not apply to other types of scanning agents used for other imaging procedures, including iodine-based contrast used in X-ray and computed tomography (CT) imaging or radioisotopes used in PET or SPECT nuclear imaging.

For more information, watch the VIDEO “MRI Gadolinium Contrast Retention in the Brain.” This is an interview with Emanuel Kanal, M.D., director of MRI services and professor of radiology and neuroradiology at the University of Pittsburgh Medical Center, at RSNA 2016. He was involved in the key studies regarding gadolinium retention in the brain.

Read the article Gadolinium May Remain in Brain After Contrast MRI

Read the article MRIs During Pregnancy Are Safe, But Gadolinium Scans May Increase Risk to Fetus

 

For more information: www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm559709.htm

 


Related Content

News | Cardiac Imaging

February 12, 2024 — According to the American Journal of Roentgenology (AJR), free-breathing cine-deep learning (DL) may ...

Time February 12, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
News | Radiology Business

January 25, 2024 — Esaote Group, a leading Italian innovator in medical imaging, today unveiled its new brand identity ...

Time January 25, 2024
arrow
News | Artificial Intelligence

January 23, 2024 — Quibim announced it has added an industry-leading cancer detection capability to its prostate tool ...

Time January 22, 2024
arrow
Feature | Contrast Media Injectors | By Christine Book

Contrast media injectors are used to inject contrast media or contrast agents to enhance the blood and perfusion in ...

Time January 17, 2024
arrow
News | Artificial Intelligence

December 22, 2023 — Quibim, a company pioneering imaging biomarkers for Precision Medicine that has created AI-based ...

Time December 22, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

December 20, 2023 — Terran Biosciences, Inc., a biotech platform company developing therapeutics and technologies for ...

Time December 20, 2023
arrow
News | Contrast Media

December 11, 2023 — Bracco Imaging S.p.A., an innovative world leader delivering end-to-end products and solutions ...

Time December 11, 2023
arrow
News | Radiopharmaceuticals and Tracers

December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco ...

Time December 06, 2023
arrow
News | Artificial Intelligence

December 5, 2023 — Radiology is under severe economic pressure as reimbursement rates fall for many common scans. At the ...

Time December 05, 2023
arrow
Subscribe Now